These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 35689207)

  • 1. Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.
    Berlak M; Tucker E; Dorel M; Winkler A; McGearey A; Rodriguez-Fos E; da Costa BM; Barker K; Fyle E; Calton E; Eising S; Ober K; Hughes D; Koutroumanidou E; Carter P; Stankunaite R; Proszek P; Jain N; Rosswog C; Dorado-Garcia H; Molenaar JJ; Hubank M; Barone G; Anderson J; Lang P; Deubzer HE; Künkele A; Fischer M; Eggert A; Kloft C; Henssen AG; Boettcher M; Hertwig F; Blüthgen N; Chesler L; Schulte JH
    Mol Cancer; 2022 Jun; 21(1):126. PubMed ID: 35689207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
    Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
    Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed
    Liu T; Merguerian MD; Rowe SP; Pratilas CA; Chen AR; Ladle BH
    Cold Spring Harb Mol Case Stud; 2021 Aug; 7(4):. PubMed ID: 34210658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse.
    Chen L; Humphreys A; Turnbull L; Bellini A; Schleiermacher G; Salwen H; Cohn SL; Bown N; Tweddle DA
    Oncotarget; 2016 Dec; 7(52):87301-87311. PubMed ID: 27888620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesenchymal-Type Neuroblastoma Cells Escape ALK Inhibitors.
    Westerhout EM; Hamdi M; Stroeken P; Nowakowska NE; Lakeman A; van Arkel J; Hasselt NE; Bleijlevens B; Akogul N; Haneveld F; Chan A; van Sluis P; Zwijnenburg D; Volckmann R; van Noesel CJM; Adameyko I; van Groningen T; Koster J; Valentijn LJ; van Nes J; Versteeg R
    Cancer Res; 2022 Feb; 82(3):484-496. PubMed ID: 34853072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling.
    Coggins GE; Farrel A; Rathi KS; Hayes CM; Scolaro L; Rokita JL; Maris JM
    Cancer Res; 2019 Dec; 79(24):6204-6214. PubMed ID: 31672841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.
    Guan J; Fransson S; Siaw JT; Treis D; Van den Eynden J; Chand D; Umapathy G; Ruuth K; Svenberg P; Wessman S; Shamikh A; Jacobsson H; Gordon L; Stenman J; Svensson PJ; Hansson M; Larsson E; Martinsson T; Palmer RH; Kogner P; Hallberg B
    Cold Spring Harb Mol Case Stud; 2018 Aug; 4(4):. PubMed ID: 29907598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma.
    Valencia-Sama I; Kee L; Christopher G; Ohh M; Layeghifard M; Shlien A; Hayes MN; Irwin MS
    Cancer Res Commun; 2023 Dec; 3(12):2608-2622. PubMed ID: 38032104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status.
    Trigg RM; Lee LC; Prokoph N; Jahangiri L; Reynolds CP; Amos Burke GA; Probst NA; Han M; Matthews JD; Lim HK; Manners E; Martinez S; Pastor J; Blanco-Aparicio C; Merkel O; de Los Fayos Alonso IG; Kodajova P; Tangermann S; Högler S; Luo J; Kenner L; Turner SD
    Nat Commun; 2019 Nov; 10(1):5428. PubMed ID: 31780656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma.
    Pucci P; Lee LC; Han M; Matthews JD; Jahangiri L; Schlederer M; Manners E; Sorby-Adams A; Kaggie J; Trigg RM; Steel C; Hare L; James ER; Prokoph N; Ducray SP; Merkel O; Rifatbegovic F; Luo J; Taschner-Mandl S; Kenner L; Burke GAA; Turner SD
    Nat Commun; 2024 Apr; 15(1):3422. PubMed ID: 38653965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models.
    Tucker ER; Jiménez I; Chen L; Bellini A; Gorrini C; Calton E; Gao Q; Che H; Poon E; Jamin Y; Martins Da Costa B; Barker K; Shrestha S; Hutchinson JC; Dhariwal S; Goodman A; Del Nery E; Gestraud P; Bhalshankar J; Iddir Y; Saberi-Ansari E; Saint-Charles A; Geoerger B; Marques Da Costa ME; Pierre-Eugène C; Janoueix-Lerosey I; Decaudin D; Nemati F; Carcaboso AM; Surdez D; Delattre O; George SL; Chesler L; Tweddle DA; Schleiermacher G
    Clin Cancer Res; 2023 Apr; 29(7):1317-1331. PubMed ID: 36602782
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Valencia-Sama I; Ladumor Y; Kee L; Adderley T; Christopher G; Robinson CM; Kano Y; Ohh M; Irwin MS
    Cancer Res; 2020 Aug; 80(16):3413-3423. PubMed ID: 32586982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study.
    Tan DS; Thomas M; Kim DW; Szpakowski S; Urban P; Mehra R; Chow LQM; Sharma S; Solomon BJ; Felip E; Camidge DR; Vansteenkiste J; Petruzzelli L; Pantano S; Shaw AT
    Lung Cancer; 2022 Jan; 163():7-13. PubMed ID: 34890832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual
    Wood AC; Krytska K; Ryles HT; Infarinato NR; Sano R; Hansel TD; Hart LS; King FJ; Smith TR; Ainscow E; Grandinetti KB; Tuntland T; Kim S; Caponigro G; He YQ; Krupa S; Li N; Harris JL; Mossé YP
    Clin Cancer Res; 2017 Jun; 23(11):2856-2868. PubMed ID: 27986745
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis.
    Ek T; Ibrahim RR; Vogt H; Georgantzi K; Träger C; Gaarder J; Djos A; Rahmqvist I; Mellström E; Pujol-Calderón F; Vannas C; Hansson L; Fagman H; Treis D; Fransson S; Österlund T; Chuang TP; Verhoeven BM; Ståhlberg A; Palmer RH; Hallberg B; Martinsson T; Kogner P; Dalin M
    Cancer Res Commun; 2024 Sep; 4(9):2553-2564. PubMed ID: 39177282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer.
    Redaelli S; Ceccon M; Zappa M; Sharma GG; Mastini C; Mauri M; Nigoghossian M; Massimino L; Cordani N; Farina F; Piazza R; Gambacorti-Passerini C; Mologni L
    Cancer Res; 2018 Dec; 78(24):6866-6880. PubMed ID: 30322862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.
    Berko ER; Witek GM; Matkar S; Petrova ZO; Wu MA; Smith CM; Daniels A; Kalna J; Kennedy A; Gostuski I; Casey C; Krytska K; Gerelus M; Pavlick D; Ghazarian S; Park JR; Marachelian A; Maris JM; Goldsmith KC; Radhakrishnan R; Lemmon MA; Mossé YP
    Nat Commun; 2023 May; 14(1):2601. PubMed ID: 37147298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.
    Bresler SC; Wood AC; Haglund EA; Courtright J; Belcastro LT; Plegaria JS; Cole K; Toporovskaya Y; Zhao H; Carpenter EL; Christensen JG; Maris JM; Lemmon MA; Mossé YP
    Sci Transl Med; 2011 Nov; 3(108):108ra114. PubMed ID: 22072639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
    Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting anaplastic lymphoma kinase in neuroblastoma.
    Umapathy G; Mendoza-Garcia P; Hallberg B; Palmer RH
    APMIS; 2019 May; 127(5):288-302. PubMed ID: 30803032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.